Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022

Anna Solastie, Tuomo Nieminen, Nina Ekström, Hanna Nohynek, Lasse Lehtonen, Arto A. Palmu, Merit Melin
doi: https://doi.org/10.1101/2023.02.17.23286042

Article Information

doi 
https://doi.org/10.1101/2023.02.17.23286042
History 
  • February 23, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Anna Solastie1,*,
  2. Tuomo Nieminen2,
  3. Nina Ekström1,
  4. Hanna Nohynek1,
  5. Lasse Lehtonen3,
  6. Arto A. Palmu4 and
  7. Merit Melin1
  1. 1Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland
  2. 2Department of Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland
  3. 3HUS Diagnostic Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  4. 4The Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Tampere, Finland. FVR – Finnish Vaccine Research, Tampere, Finland
  1. ↵*Correspondence: Anna Solastie anna.solastie{at}thl.fi
Back to top
Posted February 23, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Changes in SARS-CoV-2 seroprevalence and population immunity in Finland, 2020–2022
Anna Solastie, Tuomo Nieminen, Nina Ekström, Hanna Nohynek, Lasse Lehtonen, Arto A. Palmu, Merit Melin
medRxiv 2023.02.17.23286042; doi: https://doi.org/10.1101/2023.02.17.23286042
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area